inclisiran   Click here for help

GtoPdb Ligand ID: 13624

Synonyms: ALN-60212 | ALN-PCSsc | Leqvio®
Approved drug
inclisiran is an approved drug (EMA (2020), FDA & UK MHRA (2021))
Compound class: Nucleic acid
Comment: Inclisiran is a small interfering RNA (siRNA) class drug that targets the proprotein convertase subtilisin kexin type 9 (PCSK9) mRNA, to reduce production of the PCSK9 protein [6].
Individual nucleotides are chemically modified to improve stability, and the structure has terminal GalNac (sugar) conjugation for hepatic targeted delivery. We have been unable to locate a full chemical SMILES for the drug, or its HELM notation.
Classification Click here for help
Compound class Nucleic acid
Compound subclass siRNA
Target PCSK9 mRNA
Approved drug? Yes. FDA (2021)  |  EMA (2020)  |  UK MHRA (2021)
International Nonproprietary Names Click here for help
INN number INN
10268 inclisiran
Synonyms Click here for help
ALN-60212 | ALN-PCSsc | Leqvio®
Database Links Click here for help
CAS Registry No. 1639324-58-5 (source: WHO INN record)
ChEMBL Ligand CHEMBL5095052
DrugBank Ligand DB14901
GtoPdb PubChem SID 504705443
Search PubMed clinical trials inclisiran
Search PubMed titles inclisiran
Search PubMed titles/abstracts inclisiran